Video

Ki-67 shows proven clinical utility as a predictive biomarker for breast cancer


 

Community Oncology Founding Editor Dr. Lee Schwartzberg, spoke with Dr. Joyce O'Shaughnessy at the Oncology Practice Summit in Las Vegas about emerging molecular biomarkers in breast cancer and shares some case-based treatment options to illustrate how these new predictive tools can be used.

The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Schwartzberg was chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology and The Oncology Report.

Recommended Reading

Lipid metabolism genes linked to breast cancer subtype
Breast Cancer ICYMI
Breast cancer: Cardiac risk increases with radiation dose to heart
Breast Cancer ICYMI
Contralateral prophylactic mastectomy adds complications
Breast Cancer ICYMI
CancerLinQ prototype leverages 'Big Data'
Breast Cancer ICYMI
Mammography screening at 75 may have value
Breast Cancer ICYMI
What's in a name: Is the moniker 'palliative care' too loaded?
Breast Cancer ICYMI
Dexamethasone eases end-of-life cancer-related fatigue
Breast Cancer ICYMI
USPSTF draft recommendations update chemoprevention for breast cancer
Breast Cancer ICYMI
Weight loss, exercise can impact cancer incidence and recurrence
Breast Cancer ICYMI
Community Oncology Podcast: T-DM1 in HER-2 positive breast cancer
Breast Cancer ICYMI